Zoetis Inc (NYSE:ZTS) insider Heidi C. Chen sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $93.51, for a total transaction of $233,775.00. Following the completion of the transaction, the insider now directly owns 17,662 shares in the company, valued at approximately $1,651,573.62. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Zoetis stock traded down $0.16 during midday trading on Thursday, hitting $90.41. 2,992,718 shares of the company’s stock were exchanged, compared to its average volume of 2,520,083. The company has a debt-to-equity ratio of 3.04, a current ratio of 4.06 and a quick ratio of 2.63. Zoetis Inc has a 12 month low of $70.20 and a 12 month high of $96.57. The stock has a market cap of $43.51 billion, a price-to-earnings ratio of 37.67, a PEG ratio of 1.79 and a beta of 0.99.
Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.06. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The company had revenue of $1.48 billion for the quarter, compared to analysts’ expectations of $1.46 billion. During the same period in the prior year, the business earned $0.65 EPS. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. On average, equities analysts expect that Zoetis Inc will post 3.11 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th were issued a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend was Monday, November 19th. Zoetis’s payout ratio is 20.83%.
Institutional investors have recently modified their holdings of the business. Signature Estate & Investment Advisors LLC bought a new position in Zoetis during the 3rd quarter worth about $112,000. Capital Bank & Trust Co grew its holdings in Zoetis by 206.5% during the 3rd quarter. Capital Bank & Trust Co now owns 1,269 shares of the company’s stock worth $116,000 after acquiring an additional 855 shares in the last quarter. Capital Guardian Trust Co. bought a new position in Zoetis during the 3rd quarter worth about $117,000. Sun Life Financial INC boosted its holdings in shares of Zoetis by 604.3% in the 2nd quarter. Sun Life Financial INC now owns 1,310 shares of the company’s stock valued at $112,000 after buying an additional 1,124 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Zoetis by 3,033.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock valued at $120,000 after buying an additional 1,365 shares in the last quarter. Institutional investors own 89.94% of the company’s stock.
Several research analysts recently commented on ZTS shares. Argus set a $105.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research note on Tuesday, November 13th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Wednesday, October 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $98.00 price target on shares of Zoetis in a research note on Monday, October 1st. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price target on the stock. in a research note on Tuesday, August 21st. They noted that the move was a valuation call. Finally, Morgan Stanley set a $100.00 price target on shares of Zoetis and gave the stock a “hold” rating in a research note on Friday, November 2nd. Six research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $94.00.
Zoetis Company Profile
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Featured Story: Consumer behavior in bull markets